ROS1 and non-small cell lung carcinoma: Its inability to penetrate the BBB renders crizotinib unsuitable for ROS1-rearranged NSCLC patients with CNS metastasis; in such cases, entrectinib, ceritinib, repotrectinib and lorlatinib are more appropriate options since these agents were specifically engineered to penetrate the BBB.